Newron Pharmaceuticals Aktie
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 88,50 |
UBS Asset Management Switzerland AG | 3,11 |
Gefim SpA | 2,89 |
Jeffrey S. Yass | 2,89 |
Swisscanto (CH) Index Fund V - Equity Fd. Switzerland To. Res. | 0,69 |
Swisscanto (CH) Index Fund V - Equity Small & Mids Caps Swit. | 0,64 |
CSIF (CH) Umbrella - Eq. Switzerland Total Market Index Blue | 0,59 |
CSIF (CH) Umbrella - Equity Switzerland Small & Mid Cap | 0,56 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. CHF) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 65 | 41 | 41 | 28 | 18 |
Summe Anlagevermögen | 0 | 14 | 11 | 9 | 6 |
Summe Aktiva | 66 | 55 | 52 | 37 | 24 |
Bilanz (in Mio. CHF) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 18 | 28 | 45 | 45 | 45 |
Summe Fremdkapital | 26 | 37 | 49 | 51 | 52 |
Summe Eigenkapital | 40 | 19 | 3 | -14 | -28 |
Summe Passiva | 66 | 55 | 52 | 37 | 24 |
Adresse
via Antonio Meucci 3, 20091 Bresso | |
Telefon | +39 (02) 610-3461 |
Fax | +39 (02) 610-34654 |
Internet | https://www.newron.com/ |
Management
Dennis Dionne
Vice President-Commercial Affairs |
Filippo Moriggia
Vice President-Operations |
Gillian Dines
Non-Executive Director |
Laura Faravelli
Executive Vice President-Business Development |
Luca Benatti
Independent Non-Executive Director |
Margarita I. Chavez
Independent Director |
Patrick J. Langlois
Independent Non-Executive Director |
Ravi Anand
Chief Medical Officer |
Roberto Galli
Chief Financial Officer |
Stefan Weber
Chief Executive Officer & Director |
Ulrich Köstlin
Non-Executive Chairman |